Mark Waltham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark Waltham has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Galina Polekhina
Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
3 shared publications - Jake Shortt
Monash University
3 shared publications - Stephen Opat
Department of Haematology, Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
3 shared publications Daniella Brasacchio
Monash Hematology, Monash Health, Melbourne, VIC, Australia
2 shared publications- Gareth Peter Gregory
School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia, Australia
2 shared publications - Aditya Tedjaseputra
King's College London, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse
Background: Next generation sequencing (NGS) of cell free tumour DNA (ctDNA) provides a snapshot of lymphoma mutations correlating with tumour burden. We evaluated the ability of ctDNA to molecularly profile and track disease burden in patients with aggressive‐B‐cell lymphoma.Methods: Patients were prospectively recruited from the ‘standard‐of‐care’ clinic based on high‐risk clinical features. Using error‐corrected, capture‐based NGS of ctDNA, we profiled 17 patients receiving treatment for diffuse large B‐cell lymphoma to determine the utility of molecular profiling and dynamic response assessment through to measurable residual disease (MRD) states.Results: Somatic mutations were detected at baseline in 17/17 patients, including 13 with phased variants that could be leveraged for enhanced assay sensitivity. Early molecular response (EMR; ≥ 2 log10 reduction in ctDNA during cycle 1) was predictive of end‐of‐treatment complete metabolic response (CMR; EMR rate 100% vs. no EMR 12.5%, p = 0.0014) and 24‐month progression free survival (PFS; no progression events for those in EMR vs. no EMR 4.57 months, p = 0.015). Only 1/12 MRD‐negative patients relapsed. Interestingly, all three late relapses demonstrated histological infidelity and potential clonal evolution based on ctDNA results.Conclusion: These data further support the potential utility of molecular lymphoma profiling by ctDNA analysis and the predictive value of EMR as reported by independent groups. We also posit that ctDNA alone is insufficient to diagnose late relapses, where shared mutations may associate with differential histopathology.
Open AccessDynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse
Background: Next generation sequencing (NGS) of cell free tumour DNA (ctDNA) provides a snapshot of lymphoma mutations correlating with tumour burden. We evaluated the ability of ctDNA to molecularly profile and track disease burden in patients with aggressive‐B‐cell lymphoma.Methods: Patients were prospectively recruited from the ‘standard‐of‐care’ clinic based on high‐risk clinical features. Using error‐corrected, capture‐based NGS of ctDNA, we profiled 17 patients receiving treatment for diffuse large B‐cell lymphoma to determine the utility of molecular profiling and dynamic response assessment through to measurable residual disease (MRD) states.Results: Somatic mutations were detected at baseline in 17/17 patients, including 13 with phased variants that could be leveraged for enhanced assay sensitivity. Early molecular response (EMR; ≥ 2 log10 reduction in ctDNA during cycle 1) was predictive of end‐of‐treatment complete metabolic response (CMR; EMR rate 100% vs. no EMR 12.5%, p = 0.0014) and 24‐month progression free survival (PFS; no progression events for those in EMR vs. no EMR 4.57 months, p = 0.015). Only 1/12 MRD‐negative patients relapsed. Interestingly, all three late relapses demonstrated histological infidelity and potential clonal evolution based on ctDNA results.Conclusion: These data further support the potential utility of molecular lymphoma profiling by ctDNA analysis and the predictive value of EMR as reported by independent groups. We also posit that ctDNA alone is insufficient to diagnose late relapses, where shared mutations may associate with differential histopathology.
- Open Access
- 14 July 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (14) , 3531-3539
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
Using tissue whole exome sequencing (WES) and circulating tumor cell–free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group translational study sought to characterize primary and acquired molecular determinants of response and resistance of marginal zone lymphoma (MZL) to zanubrutinib for patients treated in the MAGNOLIA clinical trial. WES was performed on baseline tumor samples obtained from 18 patients. For 7 patients, ctDNA sequence was interrogated using a bespoke hybrid-capture next-generation sequencing assay for 48 targeted genes. Somatic mutations were correlated with objective response data and survival analysis using Fisher exact test and Kaplan-Meier (log-rank) method, respectively. Baseline WES identified mutations in 33 of 48 (69%) prioritized genes. NF-κB, NOTCH, or B-cell receptor (BCR) pathway genes were implicated in samples from 16 of 18 patients (89%). KMT2D mutations (n = 11) were most common, followed by FAT1 (n = 9), NOTCH1, NOTCH2, TNFAIP3 (n = 5), and MYD88 (n = 4) mutations. MYD88 or TNFAIP3 mutations correlated with improved progression-free survival (PFS). KMT2D mutations trended to worse PFS. Acquired resistance mutations PLCG2 (R665W/R742P) and BTK (C481Y/C481F) were detected in 2 patients whose disease progressed. A BTK E41K noncatalytic activating mutation was identified before treatment in 1 patient who was zanubrutinib-refractory. MYD88, TNFAIP3, and KMT2D mutations correlate with PFS in patients with relapsed/refractory MZL treated with zanubrutinib. Detection of acquired BTK and PLCG2 mutations in ctDNA while on therapy is feasible and may herald clinical disease progression. This trial was registered at https://anzctr.org.au/ as #ACTRN12619000024145.
- 14 July 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (14) , 3531-3539
Open AccessMolecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
Using tissue whole exome sequencing (WES) and circulating tumor cell–free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group translational study sought to characterize primary and acquired molecular determinants of response and resistance of marginal zone lymphoma (MZL) to zanubrutinib for patients treated in the MAGNOLIA clinical trial. WES was performed on baseline tumor samples obtained from 18 patients. For 7 patients, ctDNA sequence was interrogated using a bespoke hybrid-capture next-generation sequencing assay for 48 targeted genes. Somatic mutations were correlated with objective response data and survival analysis using Fisher exact test and Kaplan-Meier (log-rank) method, respectively. Baseline WES identified mutations in 33 of 48 (69%) prioritized genes. NF-κB, NOTCH, or B-cell receptor (BCR) pathway genes were implicated in samples from 16 of 18 patients (89%). KMT2D mutations (n = 11) were most common, followed by FAT1 (n = 9), NOTCH1, NOTCH2, TNFAIP3 (n = 5), and MYD88 (n = 4) mutations. MYD88 or TNFAIP3 mutations correlated with improved progression-free survival (PFS). KMT2D mutations trended to worse PFS. Acquired resistance mutations PLCG2 (R665W/R742P) and BTK (C481Y/C481F) were detected in 2 patients whose disease progressed. A BTK E41K noncatalytic activating mutation was identified before treatment in 1 patient who was zanubrutinib-refractory. MYD88, TNFAIP3, and KMT2D mutations correlate with PFS in patients with relapsed/refractory MZL treated with zanubrutinib. Detection of acquired BTK and PLCG2 mutations in ctDNA while on therapy is feasible and may herald clinical disease progression. This trial was registered at https://anzctr.org.au/ as #ACTRN12619000024145.
- Open Access
- 22 April 2022
- Published by Springer Nature in Leukemia
- Vol. 36 (6) , 1654-1665
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
Peripheral T-cell lymphoma (PTCL) is a rare, heterogenous malignancy with dismal outcomes at relapse. Hypomethylating agents (HMA) have an emerging role in PTCL, supported by shared mutations with myelodysplasia (MDS). Response rates to azacitidine in PTCL of follicular helper cell origin are promising. Guadecitabine is a decitabine analogue with efficacy in MDS. In this phase II, single-arm trial, PTCL patients received guadecitabine on days 1–5 of 28-day cycles. Primary end points were overall response rate (ORR) and safety. Translational sub-studies included cell free plasma DNA sequencing and functional genomic screening using an epigenetically-targeted CRISPR/Cas9 library to identify response predictors. Among 20 predominantly relapsed/refractory patients, the ORR was 40% (10% complete responses). Most frequent grade 3-4 adverse events were neutropenia and thrombocytopenia. At 10 months median follow-up, median progression free survival (PFS) and overall survival (OS) were 2.9 and 10.4 months respectively. RHOAG17V mutations associated with improved PFS (median 5.47 vs. 1.35 months; Wilcoxon p = 0.02, Log-Rank p = 0.06). 4/7 patients with TP53 variants responded. Deletion of the histone methyltransferase SETD2 sensitised to HMA but TET2 deletion did not. Guadecitabine conveyed an acceptable ORR and toxicity profile; decitabine analogues may provide a backbone for future combinatorial regimens co-targeting histone methyltransferases.
- 22 April 2022
- Published by Springer Nature in Leukemia
- Vol. 36 (6) , 1654-1665
Open AccessIntegrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
Peripheral T-cell lymphoma (PTCL) is a rare, heterogenous malignancy with dismal outcomes at relapse. Hypomethylating agents (HMA) have an emerging role in PTCL, supported by shared mutations with myelodysplasia (MDS). Response rates to azacitidine in PTCL of follicular helper cell origin are promising. Guadecitabine is a decitabine analogue with efficacy in MDS. In this phase II, single-arm trial, PTCL patients received guadecitabine on days 1–5 of 28-day cycles. Primary end points were overall response rate (ORR) and safety. Translational sub-studies included cell free plasma DNA sequencing and functional genomic screening using an epigenetically-targeted CRISPR/Cas9 library to identify response predictors. Among 20 predominantly relapsed/refractory patients, the ORR was 40% (10% complete responses). Most frequent grade 3-4 adverse events were neutropenia and thrombocytopenia. At 10 months median follow-up, median progression free survival (PFS) and overall survival (OS) were 2.9 and 10.4 months respectively. RHOAG17V mutations associated with improved PFS (median 5.47 vs. 1.35 months; Wilcoxon p = 0.02, Log-Rank p = 0.06). 4/7 patients with TP53 variants responded. Deletion of the histone methyltransferase SETD2 sensitised to HMA but TET2 deletion did not. Guadecitabine conveyed an acceptable ORR and toxicity profile; decitabine analogues may provide a backbone for future combinatorial regimens co-targeting histone methyltransferases.